Education
About Us
Working with TipRanks
Follow Us
Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.69
Previous CloseN/A
Volume34.30K
Average Volume (3M)149.45K
Market Cap
AU$19.99M
Enterprise ValueAU$3.45M
Total Cash (Recent Filing)AU$29.87M
Total Debt (Recent Filing)AU$653.00K
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$18.85M
Bulls Say, Bears Say
Bulls Say
Proprietary 3base TechnologyOwnership of the 3base™ chemistry provides a durable technical differentiation for multiplex PCR assays. That proprietary method supports broad panel design, creates higher switching costs for labs, and enables licensing or integration opportunities that can sustain competitive advantage over years.
Consumables-based Recurring RevenueA consumables-first business model (assays and repeat kit sales) generates recurring per-test revenue tied to lab utilization. This creates structural revenue visibility and operating leverage as installed base and test volumes grow, supporting long-term cash generation if adoption advances.
Low Financial LeverageMinimal debt reduces solvency and refinancing risk, giving the company flexibility to fund validation, regulatory work and commercial expansion without large interest burdens. A strong equity base supports resilience during product rollouts and industry cyclicality.
Bears Say
Persistent UnprofitabilityOngoing negative margins indicate the business has not yet converted revenue into sustainable profits. This undermines internal funding for commercialization and product development, increases reliance on external capital, and delays returns to shareholders absent material margin improvement.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow constrains the company's ability to self-fund growth, inventory and distributor support. Over months this raises the probability of capital raises, which can dilute shareholders and divert management focus from commercialization to financing.
Weak Margin SustainabilityDifficulty maintaining gross and operating margins suggests structural cost or pricing pressures versus peers. Even with revenue growth, persistent margin weakness limits free cash generation and scalability, making long-term profitability reliant on operational fixes or higher-volume adoption.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.08 and its highest was AU$0.69 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$19.99M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 167 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.35%
12-Months-Change
Fundamentals
Return on Equity
-36.16%
Trailing 12-Months
Asset Growth
-18.81%
Trailing 12-Months
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Inoviq Ltd
―